Moletest offers skin cancer screening test to primary care professionals – Mobihealth News

UK-based medical technology company, Moletest (Scotland) Ltd, is offering primary care professionals the opportunity to reduce the number of dermatology referrals to secondary care with nomela, a screening test for skin lesions suspected of melanoma.

WHY IT MATTERS

GPs and other primary care professionals will be able to use a nomela iPad to takeimages of the suspect skin lesion, which are analysed against five algorithms to provide aresult of either "no evidence of melanoma" or "melanoma not excluded.

The nomela test has been developed to assist the process of screening out melanoma, and reducing the burden on the healthcare system.

This is even more important now due to the COVID-19 crisis, where the NHS is looking to digital options and ways to reduce the need for patients to be managed and treated in a hospital setting.

The test could help to reduce the number of unnecessary dermatology referrals to secondary care by over 50%, potentially saving the NHS 125 million per year.

THE LARGER CONTEXT

Other skin imaging competitors have launched technology to support skin monitoring for patients. Earlier this year, Miiskin introduced automatic skin imaging, available in a consumer app, which enables people to take full-body photographs of their skin at home. Miiskin was one of the few select apps on the NHS Apps Library, and the first skin checking app listed on the EMIS App Library.

In February, a study published in the BMJ advised against the use of apps to assess the risk of skin cancer, stating that skin cancer detection apps cannot be relied on for accurate diagnosis, due to their variable performance.

ON THE RECORD

Bruce Murray, technical director at Moletest (Scotland) Ltd said: It is a challenge toidentifywhichskin lesionsaremelanoma,whether by inspectionwith thenaked eyeorusingtechnological advances,such as the dermatoscope.

Ourrule-outtechnologywill helptoidentify which skin lesionsdo notrequire further investigation. nomelauses the iPad Pro as a medical grade device which is centrally controlled so that it can be configured for each userand its operating system and softwareautomatically updated following performance testing.

The quality of its camera and screenensurea clearclose-up imagewith detailed edge detection.Our technical approach is to control all variable factors, including the type of device used to ensure reliable results. nomelacan deliver true innovation within this market, demonstrating thethree dimensions of value that are critical in healthcare, including clinical benefit, patientquality of life and economic value.

See the article here:
Moletest offers skin cancer screening test to primary care professionals - Mobihealth News